Safety and Immunogenicity of GlaxoSmithKline Biologicals' Herpes Zoster Vaccine 1437173A.
Phase of Trial: Phase I/II
Latest Information Update: 20 Dec 2017
At a glance
- Drugs GSK 1437173A (Primary) ; AS01B; AS01E
- Indications Herpes zoster; Varicella zoster virus infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors GlaxoSmithKline
- 27 May 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 07 Jan 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 10 Dec 2010 Planned end date changed from 1 Jun 2010 to 1 May 2011 as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History